Table 1.

Baseline characteristics before and after PSM.

Variables	Before PSM			After PSM
	TACE+L n=91n, (%)	TACE+L+PD1 n=75n, (%)	P	TACE+L n=48n, (%)	TACE+L+PD1 n=48n, (%)	P
Age			0.263			0.593
≤60	66 (72.5)	60 (80.0)		41 (85.4)	38 (79.2)
>60	25 (27.5)	15 (20.0)		7 (14.6)	10 (20.8)
Sex			0.017			1.000
Female	3 (3.3)	10 (13.3)		2 (4.2)	1 (2.1)
Male	88 (96.7)	65 (86.7)		46 (95.8)	47 (97.9)
ECOG-PS			<0.001			1.000
0	58 (63.7)	69 (92.0)		43 (89.6)	43 (89.6)
1	33 (36.3)	6 (8.0)		5 (10.4)	5 (10.4)
ALBI grade			0.292			0.320
1	34 (37.4)	37 (49.3)		20 (41.7)	25 (52.1)
2	55 (60.4)	37 (49.3)		28 (58.3)	22 (45.8)
3	2 (2.2)	1 (1.3)		0 (0)	1 (2.1)
Child-Pugh Class			0.009			0.673
A	78 (85.7)	73 (97.3)		44 (91.7)	46 (95.8)
B	13 (14.3)	2 (2.7)		4 (8.3)	2 (4.2)
Tumor diameter (cm)			0.863			0.527
≤7	34 (37.4)	29 (38.7)		20 (41.7)	16 (33.3)
>7	57 (62.6)	46 (61.3)		28 (58.3)	32 (66.7)
Tumor number (n)			0.697			0.173
≤3	28 (30.8)	21 (28.0)		10 (20.8)	17 (35.4)
>3	63 (69.2)	54 (72.0)		38 (79.2)	31 (64.6)
BCLC stage			0.727			0.511
B	20(22.0)	20 (26.7)		12 (25.0)	9 (28.8)
C	71(78.0)	55 (73.3)		36 (75.0)	39 (81.2)
AFP (ng/ml)			0.086			0.674
≤400	41 (45.1)	24 (32.0)		20 (41.7)	17 (35.4)
>400	50 (54.9)	51 (68.0)		28 (58.3)	31 (64.6)
Portal vein thrombosis			0.622			0.671
NO	33 (36.3)	30 (40.0)		19 (39.6)	16 (33.3)
Yes	58 (63.7)	45 (60.0)		29 (60.4)	32 (66.7)
Extrahepatic metastasis			0.207			0.538
NO	42 (46.2)	42 (56.0)		28 (58.3)	24 (50)
Yes	49 (53.8)	33 (44.0)		20 (41.7)	24 (50)

ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer.